MIRA | MIRA Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5400 - 1.6280
52 Week Range	0.5100 - 6.48
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	210,122
Average Volume	5,694,587
Shares Outstanding	14,780,885
Market Cap	22,910,372
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	2023-08-14

Valuation
Profitability
Growth
Health
P/E Ratio	-1.80
Forward P/E Ratio	N/A
EPS	-0.86
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2
Country	USA
Website	MIRA

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

*Chart delayed

Analyzing fundamentals for MIRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MIRA Fundamentals page.

Watching at MIRA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on MIRA Technicals page.